- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00510380
Epigenetic Markers in Growth Restricted Human Pregnancies: a Case-controlled Study
Epigenetic Markets in Growth Restricted Human Pregnancies: A Case- Control Study
This study is carried out to discover if a baby with restricted growth in the womb is subject to specific fetal programming which predisposes to the metabolic syndrome(diabetes,hypertension,heart disease) in adulthood.We have elected to first study this condition in Chinese population in Singapore with the eventual plan of studying all ethnic groups. This is important for understanding the molecular basis of adult-onset disease such as diabetes, identifying children at risk of developing this disease in future and targeting specific strategies for intervention and disease prevention.
Intrauterine fetal programming is effected through epigenetic changes similar to those previously identified in animal studies. The epigenetic markers can be found in growth restricted Chinese pregnancies in the local population.
Study Overview
Status
Conditions
Detailed Description
Fetal growth restriction is associated with accelerated postnatal weight gain and increased obesity risk in later life.International epidemiological data suggest that the phenomenon of fetal programming links poor intrauterine growth to adult disease, primarily type II diabetes, obesity and metabolic syndrome, conditions increasingly common in Singapore. Suboptimal intrauterine environmental condition s are postulated to affect fetal development through effects on developmental plasticity through epigenetic processes. These effects manifest as poor glucose resistance, insulin resistance, obesity and cardiovascular disease in later life. There is increasing animal data to support this model.
The aim of this study is to determine if epigenetic markers of the metabolic syndrome are present in selected Chinese pregnancies in Singapore.
Hypothesis:
Intrauterine fetal programming is effected through epigenetic changes similar to those previously identified in animal studies. The epigenetic markers can be found in growth restricted Chinese pregnancies in the local population.
Methodology Umbilical cords and cord blood will be collected from twenty unequivocally growth-restricted Chinese pregnancies and twenty appropriately-grown Chinese pregnancies. DNA extracted from these tissues will be subjected to a custom-made DNA methylation array probing for specific changes in 262 candidate genes important to fetal endocrine and metabolic control.
This will be done using either a methylation array or a Sequenorn 2 in the DNA extracts that have been identified through Epigen academic consortium of the Liggins Institute and UK collaborators.
Anthropometric data will be collected from the infants at birth, and subsequently at 3,6,12,18 and 24 months and we will seek differential measures of programming.
Application The discovery of biomarkers indicating shifted developmental trajectories is the most important need in developmental programming research. Birth weight alone is not a valid measure. Biomarkers predictive of later obesity and the metabolic syndrome will be invaluable in formulating preventive strategies for these diseases.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 119074
- National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Chinese women,
- Singleton pregnancies,
- fetal growth restriction diagnosed clinically and by ultrasound parameters,
- Normally grown fetuses by clinical and ultrasound criteria
Exclusion Criteria:
- Non-Chinese women
- Multiple pregnancies
- Co-existing antenatal complications including sever pre-eclampsia
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
growth-restricted Chinese pregnancies
|
|
appropriately-grown Chinese pregnancies
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yap Seng Chong, MBBS, National University Hospital, Singapore
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SIG/07072
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fetal Growth Retardation
-
Nantes University HospitalTerminatedIntra Uterine Growth RetardationFrance
-
amera mohamedUnknownThe Relationship Between Second Trimester Placental Growth Factor Level and Fetal Growth RestrictionIntra Uterine Growth RetardationEgypt
-
Johns Hopkins UniversityWithdrawnFetal Growth Retardation | Intrauterine Growth Restriction | Intrauterine Growth Retardation | Fetal Growth Restriction
-
Poitiers University HospitalCompletedIntrauterine Growth Retardation (IUGR)France
-
PfizerCompletedGrowth Disorders | Intrauterine Growth RetardationFrance
-
Van Bölge Eğitim ve Araştırma HastanesiCompletedIntrauterine RetardationTurkey
-
Ain Shams Maternity HospitalCompletedFasting | Fetal Growth Retardation, Antenatal (Disorder)
-
Merck KGaA, Darmstadt, GermanyMerck Serono S.A., GenevaCompletedChildren Born With Serious Intra-uterine Growth Retardation
-
University Hospital, GrenobleRegistre de Handicap de l'Enfant et Observatoire Périnatal (RHEOP) Isère,... and other collaboratorsUnknownStillbirth | Infant, Small for Gestational Age | Intrauterine Growth RetardationFrance
-
University of South FloridaCompleted